Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Q4 FY19 Earnings Presentation

16 slides from Alembic Pharmaceuticals's earnings presentation, March 2019

  1. Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation

    Alembic Pharmaceuticals Ltd Investor Presentation Mar-2019

  2. Slide 2: Contents

    Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7. Shareholding Pattern

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe

  4. Slide 4: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Rhizen JV for NCE research Launched first NDA wit

  5. Slide 5: Highlights – Q4FY19

    Highlights – Q4FY19 Financial Highlights India Formulations Gr% Rs in bn 0% Rs. In Billion 3.50 3.04 3.02 Particularss ( Rs. bn) Q4 LY Q4 CY Gr% 3.00 10% 10% 3% Net Sales 8.53 9.27 9% 2.50 EBITDA Pre R&D 2.81 2.84 1% 2.00 37% 35% -4% Margin % 33% 31% 1.50 R&D 1.21 1.20 -1% 1.00 53% 54% R&D % 14% 13%

  6. Slide 6: Highlights – FY19

    Highlights – FY19 Financial Highlights India Formulations Gr% Rs in bn Rs. In Billion 9% Particularss ( Rs. bn) FY18 FY19 Gr% 16.00 13.82 14.00 12.74 Net Sales 31.31 39.35 26% 10% 13% 12.00 10% EBITDA Pre R&D 10.36 13.38 29% 10.00 33% Margin % 33% 34% 34% 5% 8.00 R&D 4.11 4.98 21% 6.00 R&D % 13% 13%

  7. Slide 7: Business

    Business Key Numbers (Rs bn) Capex 6.0 6.3 4.8 39.3 31.3 31.3 8.7 6.2 6.4 5.0 4.3 4.1 FY17 FY18 FY19 Sales EBITDA R&D R&D: Manufacturing: Formulation: Vadodara , Hyderabad and USA Formulation: Oral Solids, Panelav (Oct18)* D (H1FY18) Derma (Oct18)* Oncology OSD (H1FY20) API: Vadodara and Hyderabad(P

  8. Slide 8: International Formulations

    International Formulations Sales (Rs bn) ANDA Filed Filings: 161 Approval: 89* CAGR 25% *Incl 12 tentative 29 17.8 26 14.6 20 12.4 12.1 5.9 8 7 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 R&D Spend (Rs bn) Milestones and Update 13.6 13.1 12.7 10.0  USFDA approves Aleor Derma JV plant 6.3 Aleo

  9. Slide 9: USA Generics (part of International Formulations)

    USA Generics (part of International Formulations) Sales in Million $ 47.00 Growth 15% Quarter 42.00 41.70 37.00 36.35 32.00 27.00 22.00 Q4 FY18 Q4 FY19 Sales 36.35 41.70 Sales in Million $ Annual 200.00 177.56 Growth 36% 175.00 150.00 130.38 125.00 100.00 75.00 50.00 25.00 - FY18 FY19 Sales 130.38 1

  10. Slide 10: India Formulations

    India Formulations Sales (Rs bn) Marketing Organisation 13.8 12.5 12.7  5000 + marketing team 11.8 11.0  17 marketing divisions Added new divisions in gynaecology, cardiology, gastrointestinal, urology  14% of product portfolio in NLEM Launched 43 new products SKUs in FY19 FY15 FY16 FY17 FY18 FY1

  11. Slide 11: Therapy-wise Performance Q4 '19

    Therapy-wise Performance Q4 ‘19 QTR MAR 19 QTR MAR 18 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth Growth Growth Share Growth Growth % (ORG) (ORG) % (ORG) % (PRIM) % (ORG) % (ORG) % (ORG) % (PRIM) Cardiology 11 2.11 16 10 9 2.02 7 4 Anti Diabetic 13

  12. Slide 12: Therapy-wise Performance YTD Mar FY19

    Therapy-wise Performance YTD Mar FY19 YTD MAR 19 YTD MAR 18 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth Growth Growth Share Growth Growth % (ORG) (ORG) % (ORG) % (PRIM) % (ORG) % (ORG) % (ORG) % (PRIM) Cardiology 12 2.17 20 16 6 2.03 5 6 Anti Diabe

  13. Slide 13: Strategy

    Strategy R&D Pipeline Enablers Dosage Form FY14 FY19 Oral Solids a a People: Renewed focus on HR Talent acquisition and retention Injectables r a Oncology r a Dermatology r a Process: Simple, clear structures Opthalmology r a Clear goals and empowerment Inhalation r a Focus on compliance Biologics r

  14. Slide 14: Financials – 5 years

    Financials – 5 years Sales CAGR% Sales (Rs bn) CAGR 14% Rs 20.7bn Rs 39.3bn 14% 18% 20% 15% 39.3 35% 31.6 31.3 31.3 53% 5% 20.7 45% 25% 29% FY15 FY19 FY15 FY16 FY17 FY18 FY19 International India API CAGR: 17% Net Profit (Rs bn) CAGR: 16% EBITDA (Rs bn) 32% 23% 19% 20% 21% 22% 15% 14% 13% 13% Margins

  15. Slide 15: Latest Shareholding Pattern

    Latest Shareholding Pattern % of Total Shareholding 13 Promoter & Promoter group 14 FI/FII/MF Public 73 Market capitalisation (Rs bn) Total paid-up share capital 377.03mn 118 113 103 101 Total number of shares O/S 188.52mn 86 No. of shareholders >50 K FY15 FY16 FY17 FY18 FY19

  16. Slide 16: Thank You

    THANK YOU

Alembic Pharmaceuticals — Q4 FY19 Earnings Presentation on 6ix